GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout – HBSS

GRAIL, Inc. lost over $2.2 billion in market capitalization on February 20, 2026, after its NHS-Galleri trial failed to meet its primary endpoint for early cancer detection. A securities class action lawsuit alleges the company misled investors about the trial's design and likelihood of success, claiming management knew a three-year follow-up period would be insufficient but expressed high confidence anyway. The stock plunged over 50% following the announcement.